NO20070423L - Ny anvendelse av peptidforbindelser for behandling av essensiell tremor og andre tremorsyndromer - Google Patents

Ny anvendelse av peptidforbindelser for behandling av essensiell tremor og andre tremorsyndromer

Info

Publication number
NO20070423L
NO20070423L NO20070423A NO20070423A NO20070423L NO 20070423 L NO20070423 L NO 20070423L NO 20070423 A NO20070423 A NO 20070423A NO 20070423 A NO20070423 A NO 20070423A NO 20070423 L NO20070423 L NO 20070423L
Authority
NO
Norway
Prior art keywords
tremor
treatment
peptide compounds
syndromes
new use
Prior art date
Application number
NO20070423A
Other languages
English (en)
Norwegian (no)
Inventor
Thomas Stohr
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of NO20070423L publication Critical patent/NO20070423L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20070423A 2004-06-24 2007-01-23 Ny anvendelse av peptidforbindelser for behandling av essensiell tremor og andre tremorsyndromer NO20070423L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58208404P 2004-06-24 2004-06-24
PCT/EP2005/006750 WO2006000397A1 (en) 2004-06-24 2005-06-22 Novel use of peptide compounds for treating essential tremor and other tremor syndromes

Publications (1)

Publication Number Publication Date
NO20070423L true NO20070423L (no) 2007-03-22

Family

ID=34970895

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070423A NO20070423L (no) 2004-06-24 2007-01-23 Ny anvendelse av peptidforbindelser for behandling av essensiell tremor og andre tremorsyndromer

Country Status (19)

Country Link
US (1) US7427601B2 (enExample)
EP (1) EP1758606A1 (enExample)
JP (1) JP5038892B2 (enExample)
KR (1) KR20070034477A (enExample)
CN (1) CN1964733B (enExample)
AR (1) AR049940A1 (enExample)
AU (1) AU2005256468B2 (enExample)
BR (1) BRPI0512622A (enExample)
CA (1) CA2566301C (enExample)
EA (1) EA013592B1 (enExample)
IL (1) IL179732A0 (enExample)
MX (1) MXPA06015010A (enExample)
MY (1) MY146509A (enExample)
NO (1) NO20070423L (enExample)
NZ (1) NZ551207A (enExample)
TW (1) TWI361693B (enExample)
UA (1) UA88166C2 (enExample)
WO (1) WO2006000397A1 (enExample)
ZA (1) ZA200609021B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1243262T3 (da) * 2001-03-20 2006-10-02 Sanol Arznei Schwarz Gmbh Hidtil ukendt anvendelse af en peptidklasse af forbindelser til behandling af ikke-neuropatiske, inflammatoriske smerter
ES2185606T3 (es) * 2001-03-21 2003-05-01 Sanol Arznei Schwarz Gmbh Nuevo uso de una clase de compuestos peptidicos para tratamiento de la alodinia u otros tipos diferentes de dolor cronico o fantasma.
JP4664924B2 (ja) * 2003-12-02 2011-04-06 ウーツェーベー ファルマ ゲーエムベーハー 中枢神経因性疼痛の治療のためのペプチド化合物の新規使用
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (en) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in painful diabetic neuropathy
KR20070007931A (ko) * 2004-04-16 2007-01-16 쉬바르츠파르마에이지 만성 두통의 예방 및 치료를 위한 펩티드 화합물의 용도
EP1604655A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
PL1781276T3 (pl) * 2004-08-27 2010-11-30 Ucb Pharma Gmbh Zastosowanie związków peptydowych do leczenia bólu związanego z rakiem kości, bólu indukowanego przez chemioterapię oraz nukleozydy
EP1642889A1 (en) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
US7902401B2 (en) * 2006-12-14 2011-03-08 Nps Pharmaceuticals, Inc. Fluorinated compounds
WO2007144195A2 (en) 2006-06-15 2007-12-21 Schwarz Pharma Ag Pharmaceutical composition with synergistic anticonvulsant effect
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
CA2672494A1 (en) * 2006-12-14 2008-06-19 Nps Pharmaceuticals, Inc. Use of d-serine derivatives for the treatment of anxiety disorders
US7747551B2 (en) * 2007-02-21 2010-06-29 Neurovista Corporation Reduction of classification error rates and monitoring system using an artificial class
CA2774569A1 (en) * 2009-09-23 2011-03-31 The University Of North Carolina At Chapel Hill Novel n-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents
US20110281808A1 (en) * 2010-05-14 2011-11-17 Allmax Nutrition Inc. Composition and Method for Increasing Pre Workout Thermogenics
EP2468261A1 (en) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
MX2013005974A (es) 2010-12-02 2013-07-29 Ucb Pharma Gmbh Formulacion de lacosamida de administracion una vez al dia.
EP3481387A4 (en) * 2016-08-11 2020-04-08 Ovid Therapeutics Inc METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378729A (en) 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5773475A (en) * 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
US6277825B1 (en) 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
US6589994B1 (en) 1996-08-30 2003-07-08 Nps Pharmaceuticals, Inc. Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
DK1311256T3 (da) * 2000-08-17 2005-11-28 Teva Pharma Anvendelse af derivater af valproinsyreamider og 2-valproinsyreamider til behandling eller forebyggelse af smerter og/eller hovedpinelidelser
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
AU8676301A (en) * 2000-08-25 2002-03-04 Res Corp Technologies Inc New uses for amino acid anticonvulsants
AU2002224847A1 (en) 2000-11-21 2002-06-03 U C B, S.A. N-alkylated gaba compounds, processes for their preparation and their use as medicaments
US20040116505A1 (en) * 2001-02-23 2004-06-17 Gregory Krauss Treatment of tics, tremors and related disorders
DK1243262T3 (da) 2001-03-20 2006-10-02 Sanol Arznei Schwarz Gmbh Hidtil ukendt anvendelse af en peptidklasse af forbindelser til behandling af ikke-neuropatiske, inflammatoriske smerter
ES2185606T3 (es) 2001-03-21 2003-05-01 Sanol Arznei Schwarz Gmbh Nuevo uso de una clase de compuestos peptidicos para tratamiento de la alodinia u otros tipos diferentes de dolor cronico o fantasma.
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6828462B2 (en) * 2001-11-07 2004-12-07 Merz Pharma Gmbh & Co. Kgaa Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
AU2003283958A1 (en) * 2002-09-13 2004-04-30 Elan Pharmaceuticals, Inc. Method of treating tremors
CA2544467C (en) 2002-11-18 2014-02-18 John M. Stewart Paralytic peptide for use in neuromuscular therapy
US20050227961A1 (en) 2004-04-08 2005-10-13 Vela Pharmaceuticals, Inc. Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome
EP1604654A1 (en) 2004-05-18 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating dyskinesia
EP1604656A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)

Also Published As

Publication number Publication date
CA2566301C (en) 2011-06-14
TWI361693B (en) 2012-04-11
CN1964733A (zh) 2007-05-16
EA200700108A1 (ru) 2007-06-29
EP1758606A1 (en) 2007-03-07
KR20070034477A (ko) 2007-03-28
MXPA06015010A (es) 2007-03-26
CA2566301A1 (en) 2006-01-05
UA88166C2 (ru) 2009-09-25
MY146509A (en) 2012-08-15
NZ551207A (en) 2010-07-30
EA013592B1 (ru) 2010-06-30
CN1964733B (zh) 2012-05-23
WO2006000397A1 (en) 2006-01-05
JP5038892B2 (ja) 2012-10-03
US20050288234A1 (en) 2005-12-29
AR049940A1 (es) 2006-09-13
AU2005256468A1 (en) 2006-01-05
ZA200609021B (en) 2008-04-30
BRPI0512622A (pt) 2008-03-25
AU2005256468B2 (en) 2010-12-09
US7427601B2 (en) 2008-09-23
IL179732A0 (en) 2007-05-15
JP2008503533A (ja) 2008-02-07
TW200603823A (en) 2006-02-01

Similar Documents

Publication Publication Date Title
NO20070423L (no) Ny anvendelse av peptidforbindelser for behandling av essensiell tremor og andre tremorsyndromer
NO20071937L (no) Fremgangsmater og mellomprodukter for fremstilling av cysteinproteaseinhibitorer
CY1108738T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για την αγωγη του πονου
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
ATE423122T1 (de) Kondensierte heterocyclen als inhibitoren von glutamatracemase (muri)
DK1853602T3 (da) Kemiske forbindelser
CY1108275T1 (el) Χημικες ενωσεις
MX2008002293A (es) Uso novedoso de compuestos peptidicos para tratar dolor muscular.
EA201070422A1 (ru) Производные оксадиазола
EA200602221A1 (ru) Новое применение пептидных соединений для лечения боли при тригеминальной невралгии
NO20071585L (no) Ny anvendelse av peptidforbindelser for behandling av benkreftsmerte, kjemoterapi- og nucleosidfremkalt smerte
NO20065251L (no) Anvendelse av peptidiske forbindelser for profilakse og behandling av kronisk hodepine
DK1696905T3 (da) Substituerede 2-aminotetraliner til forebyggende behandling af Morbus Parkinson
EA200702363A1 (ru) Новые лиганды гистамина h-рецептора и их терапевтические применения
NO20054494L (no) Peptidvektorer
MY158069A (en) Tricyclic compound and pharmaceutical use thereof
EA200601079A1 (ru) Способы защиты от радиации с использованием флагеллина
DE60220385D1 (de) Benzimidazole zur behandlung sexueller fehlfunktionen
DK1686997T3 (da) Inhibitorer af mutantformen af KIT
DE60333205D1 (de) Histaminika zur behandlung von allergischer rhinitis
ECSP055844A (es) Nuevos compuestos triciclicos
EA200700400A1 (ru) Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
SE0002739D0 (sv) New use
DE602005010607D1 (de) Zyklosporinanalog

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application